Scotiabank Initiates Coverage On Rocket Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Rocket Pharmaceuticals with a Sector Outperform rating and set a price target of $50.
October 16, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has initiated coverage on Rocket Pharmaceuticals with a Sector Outperform rating and a price target of $50, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a $50 price target by Scotiabank suggests a positive outlook for Rocket Pharmaceuticals. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100